Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Tumor Origins Through Genomic Profiles.

Liu ET, Mockus SM.

JAMA Oncol. 2019 Nov 14. doi: 10.1001/jamaoncol.2019.3981. [Epub ahead of print] No abstract available.

PMID:
31725824
2.

Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance.

Hill DP, Harper A, Malcolm J, McAndrews MS, Mockus SM, Patterson SE, Reynolds T, Baker EJ, Bult CJ, Chesler EJ, Blake JA.

BMC Cancer. 2019 Nov 4;19(1):1039. doi: 10.1186/s12885-019-6278-9.

3.

Utility of the JAX Clinical Knowledgebase in capture and assessment of complex genomic cancer data.

Patterson SE, Statz CM, Yin T, Mockus SM.

NPJ Precis Oncol. 2019 Jan 15;3:2. doi: 10.1038/s41698-018-0073-y. eCollection 2019.

4.

High-resolution deconstruction of evolution induced by chemotherapy treatments in breast cancer xenografts.

Kim H, Kumar P, Menghi F, Noorbakhsh J, Cerveira E, Ryan M, Zhu Q, Ananda G, George J, Chen HC, Mockus S, Zhang C, Yang Y, Keck J, Karuturi RKM, Bult CJ, Lee C, Liu ET, Chuang JH.

Sci Rep. 2018 Dec 18;8(1):17937. doi: 10.1038/s41598-018-36184-8.

5.

Barriers preventing the adoption of comprehensive cancer genomic profiling in the clinic.

Statz CM, Patterson SE, Mockus SM.

Expert Rev Mol Diagn. 2017 Jun;17(6):549-555. doi: 10.1080/14737159.2017.1319280. Epub 2017 Apr 18. Review.

PMID:
28402162
6.

Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.

VanderLaan PA, Rangachari D, Mockus SM, Spotlow V, Reddi HV, Malcolm J, Huberman MS, Joseph LJ, Kobayashi SS, Costa DB.

Lung Cancer. 2017 Apr;106:17-21. doi: 10.1016/j.lungcan.2017.01.011. Epub 2017 Jan 25.

7.

mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review.

Statz CM, Patterson SE, Mockus SM.

Target Oncol. 2017 Feb;12(1):47-59. doi: 10.1007/s11523-016-0453-6. Review.

PMID:
27503005
8.

Somatic gene mutation analysis of triple negative breast cancers.

Dillon JL, Mockus SM, Ananda G, Spotlow V, Wells WA, Tsongalis GJ, Marotti JD.

Breast. 2016 Oct;29:202-7. doi: 10.1016/j.breast.2016.06.018. Epub 2016 Jul 7.

PMID:
27397723
9.

Molecular Genetic Analysis of Ovarian Brenner Tumors and Associated Mucinous Epithelial Neoplasms: High Variant Concordance and Identification of Mutually Exclusive RAS Driver Mutations and MYC Amplification.

Tafe LJ, Muller KE, Ananda G, Mitchell T, Spotlow V, Patterson SE, Tsongalis GJ, Mockus SM.

Am J Pathol. 2016 Mar;186(3):671-7. doi: 10.1016/j.ajpath.2015.11.008. Epub 2016 Jan 18.

10.

The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies.

Patterson SE, Liu R, Statz CM, Durkin D, Lakshminarayana A, Mockus SM.

Hum Genomics. 2016 Jan 16;10:4. doi: 10.1186/s40246-016-0061-7.

11.

Clinical Trials in Precision Oncology.

Mockus SM, Patterson SE, Statz C, Bult CJ, Tsongalis GJ.

Clin Chem. 2016 Mar;62(3):442-8. doi: 10.1373/clinchem.2015.247437. Epub 2015 Nov 25. Review.

12.

Development and validation of the JAX Cancer Treatment Profileā„¢ for detection of clinically actionable mutations in solid tumors.

Ananda G, Mockus S, Lundquist M, Spotlow V, Simons A, Mitchell T, Stafford G, Philip V, Stearns T, Srivastava A, Barter M, Rowe L, Malcolm J, Bult C, Karuturi RK, Rasmussen K, Hinerfeld D.

Exp Mol Pathol. 2015 Feb;98(1):106-12. doi: 10.1016/j.yexmp.2014.12.009. Epub 2015 Jan 3.

13.

The Comparative Toxicogenomics Database: update 2011.

Davis AP, King BL, Mockus S, Murphy CG, Saraceni-Richards C, Rosenstein M, Wiegers T, Mattingly CJ.

Nucleic Acids Res. 2011 Jan;39(Database issue):D1067-72. doi: 10.1093/nar/gkq813. Epub 2010 Sep 22.

14.

Building resilience in children of mothers who have co-occurring disorders and histories of violence: intervention model and implementation issues.

Finkelstein N, Rechberger E, Russell LA, VanDeMark NR, Noether CD, O'Keefe M, Gould K, Mockus S, Rael M.

J Behav Health Serv Res. 2005 Apr-Jun;32(2):141-54.

PMID:
15834264
15.

Mechanism of SNARE protein binding and regulation of Cav2 channels by phosphorylation of the synaptic protein interaction site.

Yokoyama CT, Myers SJ, Fu J, Mockus SM, Scheuer T, Catterall WA.

Mol Cell Neurosci. 2005 Jan;28(1):1-17.

PMID:
15607937
16.

Intersubunit binding domains within tyrosine hydroxylase and tryptophan hydroxylase.

Yohrling GJ 4th, Jiang GC, Mockus SM, Vrana KE.

J Neurosci Res. 2000 Aug 1;61(3):313-20.

PMID:
10900078
17.

Identification of amino-terminal sequences contributing to tryptophan hydroxylase tetramer formation.

Yohrling GJ 4th, Mockus SM, Vrana KE.

J Mol Neurosci. 1999 Feb;12(1):23-34.

PMID:
10636468
18.

Advances in the molecular characterization of tryptophan hydroxylase.

Mockus SM, Vrana KE.

J Mol Neurosci. 1998 Jun;10(3):163-79. Review.

PMID:
9770640
19.

Tyrosine hydroxylase and tryptophan hydroxylase do not form heterotetramers.

Mockus SM, Yohrling GJ 4th, Vrana KE.

J Mol Neurosci. 1998 Feb;10(1):45-51.

PMID:
9589369
20.

Carboxyl terminal deletion analysis of tryptophan hydroxylase.

Mockus SM, Kumer SC, Vrana KE.

Biochim Biophys Acta. 1997 Oct 17;1342(2):132-40.

PMID:
9392522
21.

Amino-terminal analysis of tryptophan hydroxylase: protein kinase phosphorylation occurs at serine-58.

Kumer SC, Mockus SM, Rucker PJ, Vrana KE.

J Neurochem. 1997 Oct;69(4):1738-45.

22.
23.

Population genetic study of the human dopamine transporter gene (DAT1).

Doucette-Stamm LA, Blakely DJ, Tian J, Mockus S, Mao JI.

Genet Epidemiol. 1995;12(3):303-8.

PMID:
7557351

Supplemental Content

Loading ...
Support Center